Scroll for more


Feb 22, 2018 announcements

BenevolentAI acquires advanced Cambridge research facility to accelerate its AI-enabled drug development

Acquisition creates first AI company capable of covering entire drug development process from drug discovery to clinical development Cambridge research facility will advance BenevolentAI drug programmes into the clinic more quickly and at a much larger scale.